Innate-Sobi deal advances lacutamab toward accelerated approval, unlocking milestone upside
Innate Pharma and Sobi announced a strategic partnership to initiate TELLOMAK-3, the Phase 3 CTCL confirmatory trial for lacutamab, targeting accelerated approval in Sézary syndrome. Innate will receive $75 million at closing and could collect up to $505 million in milestones plus royalties, while Sobi gains exclusive global rights upon approval. Closing is contingent on antitrust clearance.
View signal analysis